International Research Updates


Today Biogen Idec reported results from a Phase 3 trial investigating dexpramipexole (dex) in people with amyotrophic lateral sclerosis (ALS). The company said that the trial failed to show slowing of functional decline or improved survival and failed to demonstrate efficacy. Based on these results, the company is discontinuing development of dexpramipexole in ALS.
FUS and TDP-43 are proteins that have a role in sporadic ALS and mutations in them will cause hereditary ALS.
Two years ago, a group led by Dr. Andrew Pieper at the University of Texas Southwestern discovered a novel compound called P7C3 (an aminopropyl carbazole) that had tremendous capability for enhancing neuron formation and protecting neurons from death.